Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

1993 • 1,579 citations

Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum

1993 • 1,119 citations

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

1995 • 1,064 citations

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

1993 • 1,064 citations

Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans

1994 • 868 citations

Insulin Secretion in Response to Glycemic Stimulus: Relation of Delayed Initial Release to Carbohydrate intolerance in Mild Diabetes Mellitus*

1967 • 817 citations

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

1995 • 741 citations

The incretin concept today

1979 • 730 citations

Glucagon-Like Peptides

1998 • 548 citations

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.

1998 • 480 citations

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

1996 • 460 citations

Gastric emptying and release of incretin hormones after glucose ingestion in humans.

1996 • 416 citations

Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.

1991 • 371 citations

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

1998 • 309 citations

Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig

1996 • 291 citations

Phenotype of fatty Due to Gln269Pro Mutation in the Leptin Receptor (Lepr)

1996 • 289 citations

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM

1996 • 286 citations

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

1995 • 283 citations

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM

1997 • 272 citations

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

1995 • 270 citations

Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide

1998 • 260 citations

Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor

1996 • 248 citations

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)- (7-36) amide in type 2 (noninsulin-dependent) diabetic patients

1996 • 239 citations

Physiological Importance of Deficiency in Early Prandial Insulin Secretion in Non-Insulin-Dependent Diabetes

1988 • 216 citations

Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7?36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships

1995 • 199 citations

Glucagon-like peptide-1 is a physiological incretin in rat.

1995 • 193 citations

Glucagon-like peptides

1998 • 191 citations

Reduction of the Incretin Effect in Rats by the Glucagon-Like Peptide 1 Receptor Antagonist Exendin (9–39) Amide

1995 • 180 citations

Dose—Response Relationships

1987 • 175 citations

Preliminary report Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7–36)NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake

1996 • 150 citations

Gastric Inhibitory Polypeptide

1982 • 149 citations

The role of the free cytosolic calcium level in beta-cell signal transduction by gastric inhibitory polypeptide and glucagon-like peptide I(7-37).

1993 • 146 citations

Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM

1994 • 138 citations

Effects of Glucagon-Like Peptide-1 on Islet Function and Insulin Sensitivity in Noninsulin-Dependent Diabetes Mellitus¹

1997 • 129 citations

NVP-DPP728 (1-[[[2-[(5-Cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)-pyrrolidine), a Slow-Binding Inhibitor of Dipeptidyl Peptidase IV

1999 • 125 citations

Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons.

1996 • 122 citations

Effects of exercise training on muscle GLUT-4 protein content and translocation in obese Zucker rats

1993 • 121 citations

Potential Therapeutic Levels of Glucagon-Like Peptide I Achieved in Humans by a Buccal Tablet

1996 • 95 citations

Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7–36) amide on the rat pancreas

1993 • 84 citations

Involvement of dipeptidyl peptidase IV in an in vivo immune response

1992 • 81 citations

Phenotype of fatty due to Gln269Pro mutation in the leptin receptor (Lepr)

1996 • 79 citations

Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes

1988 • 69 citations

GLP-1 and GLP-17-36 Amide

1991 • 69 citations

Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide

1998 • 67 citations

The Inhibitory Effect of Glucagon-Like Peptide-1 (7-36)amide on Antral Motility is Antagonized by Its N-Terminally Truncated Primary Metabolite GLP-1 (9-36)amide

1998 • 66 citations

Glucose uptake and GLUT-4 protein distribution in skeletal muscle of the obese Zucker rat

1994 • 61 citations

Increased gene expression of lipogenic enzymes and glucose transporter in white adipose tissue of suckling and weaned obese Zucker rats

1991 • 57 citations

Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide

1995 • 53 citations

The role of the free cytosolic calcium level in beta-cell signal transduction by gastric inhibitory polypeptide and glucagon-like peptide I(7-37)

1993 • 46 citations

The measurement of gastric emptying in conscious rats by monitoring serial changes in serum acetaminophen level

1994 • 46 citations

Priming effect of glucagon-like peptide-1 (7–36) amide, glucose-dependent insulinotropic polypeptide and cholecystokinin-8 at the isolated perfused rat pancreas

1991 • 40 citations

A reliable and convenient parameter of the rate of paracetamol absorption to measure gastric emptying rate of liquids.

1997 • 28 citations

Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7?36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships

1995 • 22 citations

The relationship between early insulin release and glucose tolerance in healthy subjects

1993 • 8 citations

Gastric Inhibitory Polypeptide

1978 • 7 citations

Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1(7–36)amide on the rat pancreas

1992 • 4 citations